Perimeter Medical Imaging AI today announced CEO Jeremy Sobotta has resigned, effective June 15, due to personal reasons.
The Toronto-based company also announced its board of directors appointed Adrian Mendes at CEO, effective immediately. Sobotta will work closely with Mendes over the next few weeks to ensure a smooth transition of responsibilities.
“We are grateful for Jeremy’s many contributions and service to Perimeter, particularly his prudent management of the Company’s finances as the business transitioned from development stage to commercial stage. On behalf of the staff and the Board, we appreciate his leadership, dedication and hard work and wish him the best in his future endeavors,” Perimeter Medical Chair Suzanne Foster said in a news release.
Mendes is an experienced technology executive with 25 years of experience building and scaling technology companies across many different industries. Most recently, he was the chief operating officer at Groq, an AI hardware company.
“The hardworking team at Perimeter has done a wonderful job marrying OCT technology with world-class AI algorithms and developing products that will greatly help cancer surgery patients. I look forward to joining this amazing team as they work to deploy these products broadly and get them into the hands of surgeons everywhere,” Mendes said.
The board of directors also appointed Josh Vose to its board, effective immediately. Vose is an experienced medical device executive and corporate director with a history of scaling novel surgical technologies, particularly in breast oncology and reconstruction, according to Perimeter Medical. Most recently, he was CEO and board director at SIA Health, which was later acquired by Integra Lifesciences.
“We are excited for Adrian to join Perimeter at this exciting time in the Company’s growth as we focus on execution on commercial placements of the S-Series with continued advancement of the AI-enabled B-Series. In addition, I’d like to welcome Dr. Josh Vose to our Board; Josh will be instrumental in providing guidance to our ongoing clinical and regulatory strategy to accelerate the B-Series through clinical development and to commercialization,” Foster said.